6533b856fe1ef96bd12b294c

RESEARCH PRODUCT

FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment

Andreas FellgiebelMatthias J. MüllerPeter BartensteinArmin Scheurich

subject

Malemedicine.medical_specialtyTau proteinNeuroscience (miscellaneous)tau ProteinsKaplan-Meier EstimateSeverity of Illness IndexStereotaxic TechniquesCentral nervous system diseaseImaging Three-DimensionalDegenerative diseaseFluorodeoxyglucose F18Internal medicinemental disordersSeverity of illnessImage Processing Computer-AssistedmedicineHumansDementiaRadiology Nuclear Medicine and imagingLongitudinal StudiesCognitive declineAgedPsychiatric Status Rating ScalesbiologyCognitive disorderPrognosismedicine.diseasePsychiatry and Mental healthPositron-Emission TomographyStereotaxic techniquebiology.proteinCardiologyDementiaFemaleCognition DisordersMental Status SchedulePsychologyNeuroscienceBiomarkersFollow-Up Studies

description

Specific patterns of cortical glucose metabolism disturbances and increased CSF phospho-tau (p-tau(181)) concentrations could be demonstrated to predict cognitive decline and shift to dementia in amnestic mild cognitive impairment (MCI). But comparisons of both diagnostic tools have not been undertaken so far. The aim of the study was to compare (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) findings and CSF phospho-tau (p-tau(181)) measurements in the prediction of cognitive deterioration and conversion to dementia in MCI. During follow-up (mean 19 months) eight of 16 patients (50%) showed progressive cognitive decline, and four patients shifted to dementia. Pathological FDG-PET and elevated p-tau(181) levels both predicted deterioration. While p-tau(181) was highly sensitive for cognitive decline, FDG-PET was superior in predicting conversion to clinical dementia in MCI patients.

yearjournalcountryeditionlanguage
2006-05-07Psychiatry Research: Neuroimaging
https://doi.org/10.1016/j.pscychresns.2006.12.002